Headlines about Quanterix (NASDAQ:QTRX) have been trending positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Quanterix earned a news sentiment score of 0.27 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.8281853299857 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s rankings:
- Quanterix (QTRX) Lowered to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Quanterix Corp. (QTRX) Receives Consensus Rating of “Buy” from Brokerages (americanbankingnews.com)
- Quanterix Corp. (QTRX) Forecasted to Post Q2 2018 Earnings of ($0.28) Per Share (americanbankingnews.com)
- BTIG Research Reaffirms Buy Rating for Quanterix (QTRX) (americanbankingnews.com)
QTRX has been the topic of a number of research reports. ValuEngine raised shares of Quanterix from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. BTIG Research reissued a “buy” rating and set a $26.00 target price on shares of Quanterix in a report on Sunday, May 13th. Finally, Zacks Investment Research lowered shares of Quanterix from a “hold” rating to a “sell” rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $26.50.
Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Wednesday, May 9th. The company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.08). equities research analysts forecast that Quanterix will post -1.12 earnings per share for the current year.
Quanterix Company Profile
Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.